通货膨胀削减法案后持续的医药创新：研发支出、股权投资和业务发展的趋势。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-06-05 DOI:10.1016/j.drudis.2025.104394

Henry Dao , Fred D. Ledley

{"title":"通货膨胀削减法案后持续的医药创新：研发支出、股权投资和业务发展的趋势。","authors":"Henry Dao , Fred D. Ledley","doi":"10.1016/j.drudis.2025.104394","DOIUrl":null,"url":null,"abstract":"<div><div>There is concern that the drug pricing provisions of the US Inflation Reduction Act (IRA) could disincentivize investment in pharmaceutical innovation. This work shows that research and development (R&D) spending by pharmaceutical manufacturers, investment in biotechnology, merger and acquisition (M&A) of clinical-stage firms, and drug licensing all increased in the six quarters following passage of the IRA compared to the preceding six quarters and stabilized above pre-pandemic levels after the market disruptions of the pandemic era. These results are indicative of a robust industry that continues to invest in innovation despite the prospects of decreasing future drug prices due to the IRA.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 7","pages":"Article 104394"},"PeriodicalIF":7.5000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development\",\"authors\":\"Henry Dao , Fred D. Ledley\",\"doi\":\"10.1016/j.drudis.2025.104394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>There is concern that the drug pricing provisions of the US Inflation Reduction Act (IRA) could disincentivize investment in pharmaceutical innovation. This work shows that research and development (R&D) spending by pharmaceutical manufacturers, investment in biotechnology, merger and acquisition (M&A) of clinical-stage firms, and drug licensing all increased in the six quarters following passage of the IRA compared to the preceding six quarters and stabilized above pre-pandemic levels after the market disruptions of the pandemic era. These results are indicative of a robust industry that continues to invest in innovation despite the prospects of decreasing future drug prices due to the IRA.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 7\",\"pages\":\"Article 104394\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001072\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001072","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

有人担心，美国《通货膨胀减少法案》（IRA）的药品定价条款可能会抑制对制药创新的投资。这项工作表明，与前六个季度相比，在IRA通过后的六个季度中，制药制造商的研发支出、生物技术投资、临床阶段公司的并购和药物许可都有所增加，并在大流行时代的市场中断之后稳定在大流行前的水平之上。这些结果表明，尽管由于IRA的影响，未来药品价格可能会下降，但一个强劲的行业仍将继续投资于创新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development

There is concern that the drug pricing provisions of the US Inflation Reduction Act (IRA) could disincentivize investment in pharmaceutical innovation. This work shows that research and development (R&D) spending by pharmaceutical manufacturers, investment in biotechnology, merger and acquisition (M&A) of clinical-stage firms, and drug licensing all increased in the six quarters following passage of the IRA compared to the preceding six quarters and stabilized above pre-pandemic levels after the market disruptions of the pandemic era. These results are indicative of a robust industry that continues to invest in innovation despite the prospects of decreasing future drug prices due to the IRA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.